For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. HypoxiSense™ 680 fluorescent imaging agent detects the tumor cell surface expression of carbonic anhydrase 9 (CA IX) protein, which increases in hypoxic regions within many tumors, especially in cervical, colorectal, non-small cell lung tumors. Pairing HypoxiSense with optical fluorescent imaging technology allows you to image and quantitate tumor sub-regions undergoing hypoxia-related changes, non-invasively and in vivo.
HypoxiSense in vivo imaging reagent is ideally suited for detecting hypoxia-induced changes in CA IX expression during:
For the first time, hypoxia can be measured non-invasively in living mice and rats, as well as in ex vivo tissue samples. It's the perfect solution for the in vivo hypoxia researcher.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||HypoxiSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Angiogenesis, Arthritis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. HypoxiSense detects the tumor cell surface expression of carbonic,anhydrase 9 (CA IX) protein, which increases in hypoxic regions,within many tumors, especially in cervical, colorectal, non-small,cell lung tumors. Pairing HypoxiSense with optical fluorescent,imaging technology allows you to image and quantitate tumor,sub-regions undergoing hypoxia-related changes, non-invasively,and in vivo.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.